Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The underlying hypothesis is that vedolizumab will modify immune cell trafficking in type 1
diabetes, and that this will be enhanced by pre-treatment with etanercept. This study will
determine whether there is mechanistic evidence in support of this hypothesis and provide
preliminary information about safety, efficacy, and tolerability of vedolizumab with and
without pretreatment with etanercept in adults with type 1 diabetes (T1D)